Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VYST Winner here, PR coming very soon now is the time to load up if you have not done so already. Good luck to you:)
VYST INSIDER BUYING..."At market close on Thursday May 22nd 2014 the share price of Vystar Corporation (VYST) was just 10 cents
NOW is the time to BUY, just like the INSIDERS have been doing BEFORE the share price races to a DOLLAR PLUS"
VYST About to break 50 day MA then clear skies to .27 cents
VYST Anything under 20 cents is a great deal, 60 days from now this stock will be trading around a dollar!
VYST Accumulation at this level by smart people will soon be rewarded. Volume is going to pick up, PR coming very soon imo
VYST Since February 2014 there have been 19, YES (NINETEEN) separate INSIDER Buys recorded and filed with the SEC. For the rest of us on the outside that is a HUGE, HUGE BUY SIGNAL if ever there was one!
VYST Since February 2014 there have been 19, YES (NINETEEN) separate INSIDER Buys recorded and filed with the SEC. For the rest of us on the outside that is a HUGE, HUGE BUY SIGNAL if ever there was one!
I think VYST is about to run, I'd be scooping anything up under 15 cents if I were still preparing my position. Best of luck, good things ahead!
VYST Break out coming!
VYST-- 19 INSIDER BUYS since February, what a BUY SIGNAL if ever I saw one!
VYST News coming imo, look for PR on multi million dollar contracts
VYST Back in, Insider buys here are A VERY GOOD SIGN!
GOVX May 7th 2014 "The positive data from the Phase I trial of GOVX-B11 is another achievement for GeoVax. We are very pleased with the safety of the vaccine and its ability to enhance immune responses in infected and drug-treated patients. "
Zachs Small Cap Research
HIV vaccine developer GeoVax preps for talks with commercialization partners
Big Pharma Partenership with Geovax Coming
New update: May 7th from Zachs: "We maintain our Outperform (BUY) rating on GeoVax. Our 12-month price target is $1.00." That is over 300% gain from current share price. Great value here!!
Zachs latest rating on GOVX
GOVX Shorts are getting slowly squeezed as the share price continues to move up over the last week.
GeoVax (GOVX) price target from respected Zachs Small Cap Research estimates the share price will rise 500% in the next 12 months from approximate current levels!!!!
GOVX Getting ready to break out, lots of accumulation occurring at this level.
GeoVax (GOVX) Big Pharma partnership coming, groundwork being laid! At the 15th annual Bio Convention Robert McNally, President and CEO of GeoVax stated in an interview that GeoVax had 7 meetings before 1030am in the partnering arena.
GeoVax (GOVX) price target from respected Zachs Small Cap Research estimates the share price will rise 500% in the next 12 months from approximate current levels!!!!
GeoVax (GOVX) offers a patented HIV/AIDS Vaccine candidate that can PREVENT you from getting infected WHILE simultaneously treating those already infected AND it is in late stage clinical trials.....That is HUGE!
GeoVax (GOVX) is a small innovative biotech, it is recognized as THE LEADER In HIV/AIDS Vaccine Development With FDA Approved Late Stage Clinical Trials! Finally a HIV/AIDS Vaccine is within reach and GeoVax (GOVX) has it!
GeoVax (GOVX) is under the radar and trading now at historic lows under 40 cents a share with research and clinical trials backed by grants from the U. S. National Institutes of Health (NIH), GeoVax (GOVX) is on the cusp of potential MASSIVE, MASSIVE future revenue streams.
GeoVax (GOVX) Big Pharma partnership coming, groundwork being laid! At the 15th annual Bio Convention Robert McNally, President and CEO of GeoVax stated in an interview that GeoVax had 7 meetings before 1030am in the partnering arena.
GeoVax (GOVX) price target from respected Zachs Small Cap Research estimates the share price will rise 500% in the next 12 months from approximate current levels!!!!
GeoVax (GOVX) offers a patented HIV/AIDS Vaccine candidate that can PREVENT you from getting infected WHILE simultaneously treating those already infected AND it is in late stage clinical trials.....That is HUGE!
GeoVax (GOVX) is a small innovative biotech, it is recognized as THE LEADER In HIV/AIDS Vaccine Development With FDA Approved Late Stage Clinical Trials! Finally a HIV/AIDS Vaccine is within reach and GeoVax (GOVX) has it!
GOVX Sure, here is the link to the CEO being interviewed at the BIO conference. It is a video, at around 1 minute and 25 seconds of the interview the CEO Robert McNally, President and CEO of GeoVax stated in an interview that GeoVax had 7 meetings before 1030am partnering arena at the BIO CEO & Investor Conference.
GeoVax had 7 meetings before 1030am
GOVX A BIG PHARMA partnership coming!! GOVX is laying the groundwork!! At the 15th Annual BIO CEO & Investor Conference, Robert McNally, President and CEO of GeoVax stated in an interview that GeoVax had 7 meetings before 1030am partnering arena at the BIO CEO & Investor Conference.
Respected Zachs Small Cap Research estimates 500% gains in their price target for the next 12 months for GeoVax (GOVX) from it's approximate current levels!!
GOVX - AWESOME Information WHY you should BUY GOVX
"GeoVax (GOVX) is a biotechnology company specializing in the creation, development, and commercialization of human vaccines to combat HIV/AIDS.
BUT IT GETS EVEN BETTER:
GeoVax (GOVX) has the LEADING and most promising HIV vaccine (GOVX-B11) available, with LATE STAGE clinical trials. (That is HUGE!)
GeoVax (GOVX) has developed proprietary innovative technology, the GeoVax HIV vaccines are for use in both preventive and therapeutic programs with advance human clinical trials having yielded positive data. ( Advanced human trials with positive results is a VERY BIG DEAL!)
GeoVax (GOVX) unique AIDS vaccine technology is designed for use in uninfected people to protect them from AIDS, while recently completed non-human studies provide data to indicate GeoVax vaccines will also prove an effective treatment for those already infected. ( An HIV/AIDS Vaccine that can prevent you from getting infected WHILE simultaneously treating those already infected and it is in late stage trials.....That is HUGE!)
GeoVax (GOVX) HIV vaccine candidates are flourishing in their development while other biotechs continue to have failures in their HIV/AIDS vaccine clinical programs. In fact the FDA was so impressed with GeoVax HIV vaccine candidate results they green lighted the vaccine candidate to a phase 2b efficacy trial. (That is HUGE!)
GeoVax (GOVX) HIV vaccine candidate (GOVX-B11) has completed Phase 2a with FDA sanctioned Phase 2b efficacy trials in planning discussions with the U. S. National Institutes of Health (NIH) and the HIV Trials Network (HVTN), these are THE ONLY HIV vaccines for America and Europe clad that are entering efficacy trials. (Out of all the biotech companies in the world GeoVax is the ONLY one with Phase 2b efficacy clinical trials about to start... A VERY BIG DEAL!)
BUT IT GETS EVEN BETTER:
GeoVax (GOVX) is backed by U. S. National Institutes of Health (NIH) that has provided GeoVax with many millions to fund research and clinical trail and preventative clinical trials, most small biotechs would covet this kind of financial backing!
GeoVax (GOVX) It's been a long road, GeoVax HIV/AIDS vaccine technologies and extensive patent filings evolved over 15 years through a collaboration headed by Dr. Harriet Robinson at Emory University in Atlanta, Georgia, with researchers at the U. S. National Institutes of Health (NIH) and the U. S. Center for Disease Control and Prevention (CDC)
GeoVax (GOVX) current propriety HIV/AIDS vaccine pipeline drugs:
For Use in the America's and Western Europe:
-GOVX-B11 vaccine preventative now in Phase 2b planning with the U. S. National Institutes of Health (NIH) and the HIV Trials Network (HVTN) having successfully completed preclinical, phase1 and phase 2a clinical trials
-GOVX-B11 therapeutic phase 2 to start having successfully completed preclinical and phase 1 trials
-GOVX-B21 therapeutic phase 1 to start, preclinical successfully completed
Targeting 3rd World Countries:
-GOVX-C11 preventive vaccine currently under U. S. National Institutes of Health (NIH) grant development
-GOVX-C21 therapeutic vaccine currently under U. S. National Institutes of Health (NIH) grant development
BUT IT GETS EVEN BETTER:
GeoVax (GOVX) at the end of fiscal year 2013 had NO DEBTS on it's books, unheard of for a small biotech, thanks to government grants and support from U. S. National Institutes of Health (NIH)
GeoVax (GOVX) in 2013 GeoVax generated grant revenues of $2.4 million
GeoVax (GOVX) also reported approximately $822,000 in unused grant funds available for use as of December 31, 2013
GeoVax (GOVX) at the end of it's fiscal year on December 31 2013, GeoVax held $2.5 million in cash, an increase of $1.5 million from the previous year. Very Healthy!!
GeoVax (GOVX) with continued success in Phase II trials for it's preventive HIV vaccine, look for a big pharmaceutical partnership to assist in the commercialization of it's patented vaccines technology.
GeoVax (GOVX) GeoVax protects it's AIDS vaccine technology with a major Patent Portfolio, it has:
-Five patents controlling the AIDS vaccine manufacturing process.
-Five issued U.S. patents and Two U.S. filed patent applications related to MVA vector vaccine technology. Licensed from the NIH, these are key licensed patents for the use of MVA as a method for delivering GeoVax's HIV-1 antigens as an AIDS vaccine.
-One issued U.S. patent and three U.S. filed patent applications covering the DNA vector vaccine.
-29 additional licensed or filed patents in the USA and several other key countries on various components and compositions of our GeoVax's vaccine
BUT IT GETS EVEN BETTER:
GeoVax (GOVX) is trading near HISTORIC LOWS currently under 40 cents a share, NOW is the time to BUY, soon GeoVax may be trading at 10 times it's current price!
GeoVax (GOVX) on March 19th 2014 highly respected Zachs Small Cap Research issued an OUTPERFORM rating (essentially a BUY rating) on GeoVax giving it a 12-month price target of $1.50. Now can you see just how undervalued GeoVax is, even the Zachs rating reflects a potential 500% increase coming to GeoVax.
GeoVax (GOVX) has only 24.97M shares outstanding with a super low float of 18.85M shares (that means the share price could move up very quickly)
GeoVax (GOVX) from an investment standpoint with millions of people sadly infected with HIV/AIDS worldwide along with approximately 60 000 thousand new cases reported in the United States each year, BUYING GeoVax (GOVX) NOW is a NO_BRAINER!
With it's leading HIV vaccine (GOVX-B11) and currently THE most promising HIV vaccine under development in late stage human trials, the amazing value here is clear with potentially HUGE revenue streams coming to GeoVax in the future!
Watch this company overview and informative short 3 minute clip presented by GeoVax President and CEO Robert McNally"
GeoVax Company Overview
GOVX Money coming in now, a 30 000 BUY at the closing bell! Smart person, they know what is coming here!
GOVX Yes, BIG things coming here, share price going to start reflecting that very soon imo
GOVX has THE LEADING HIV Vaccine candidate, this current share price will not last very long imo!
GOVX Late stage clinical trial, great value here!
Huge things ahead for GOVX!
Wow, I can't believe this is trading under 30 cents!!!
CRXM - AWESOME Information WHY you should BUY CRXM
"In March 2014 TaxuCardium Pharmaceuticals (CRXM) got acquired by China-based and oncology (cancer) focused Shanxi Taxus Pharmaceuticals. The company changed it's name from Cardium Pharmaceuticals to it's current name TaxuCardium Pharmaceuticals (CRXM).
Now here is what is MOST IMPORTANT!
The NEW OWNERS Shanxi Taxus are based in Shanxi province, they grow, produce, develop and isolate Paclitaxel.
What is Paclitaxel and why will it ensure that TaxuCardium Pharmaceuticals (CRXM) share price soars this year!
Paclitaxel is coveted by pharmaceutical companies both big and small for use in anti cancer drugs for treatments including:
-Breast Cancer
-Lung Cancer
-Ovarian Cancer
-Prostrate Cancer
It is estimated that its total global sales for Paclitaxel were approximately $ 4.5 billion last year. Insiders predict that Paclitaxel for the treatment of lung and breast cancer will become China's top-selling drug AND that China Paclitaxel market sales will increase by 5 to 10 times this year.
Pharmaceutical raw materials suppliers have predicted that "there will no anti-cancer drugs found which are better than Paclitaxel in the next few years. So Paclitaxel will remain its position of backbone product in international anticancer drugs market. Its dominant market position is unshakable."
Paclitaxel is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.
Paclitaxel is what the new owners of TaxuCardium Pharmaceuticals (CRXM) DO !!!!!
They are engaged in research and development focused on the natural resource cultivation and manufacture of Paclitaxel.
-Shanxi Taxus President Zhang Jiayue stated in a media briefing that the goal of his acquisition was to "increase the company's speed of expansion into the US pharmaceutical market."
Now there is a BUY SIGNAL!!
Expect huge, huge Paclitaxel revenue streams to flow to TaxuCardium Pharmaceuticals (CRXM), currently trading under 60 cents! This is a NO-BRAINER, the share price of CRXM is only going to rise!
BUT IT GETS EVEN BETTER:
Ask yourself who knows more about the company, you or the insiders? Obviously the insiders do, on March 4th 2014, the day after the official PR about the coming Shanxi Taxus Pharmaceuticals acquisition, NINE Directors and Officers of TaxuCardium Pharmaceuticals (CRXM) acquired a total of just under 1 MILLION shares -SEC Form 4's
If insiders are acquiring shares you should be too!
Now there is a BUY SIGNAL!!
BUT IT GETS EVEN BETTER:
Before the acquisition TaxuCardium Pharmaceuticals (CRXM) looked very promising by itself, it already has has two main proprietary products:
-#1 Generx for coronary artery disease (Heart Disease) in Phase 3 FDA trials!!!!
-#2 Excellage an FDA-cleared advanced acellular biological skin substitute and wound care applications.
-TaxuCardium Pharmaceuticals (CRXM) is the leader in the field of cardiac gene therapy
-TaxuCardium Pharmaceuticals (CRXM) pipeline drug Generx for coronary artery disease has already FDA CLEARED Phase 3 clinical study!
-TaxuCardium Pharmaceuticals (CRXM) recently reported encouraging initial findings from its ASPIRE international clinical Phase 3 for pipeline drug Generx for coronary artery disease. The company reports that Generx together with Cardium's new catheter-based delivery protocol, appears to be safe and well tolerated!! (BIG STUFF)
New owners Shanxi Taxus stated they had entered into a strategic collaboration designed to support the commercial development of Generx and Excellage in China and around the world! The President of Shanxi Taxus Pharmaceuticals Zhang Jiayue stated that products are of "particular interest, specifically the ones for diabetes patients.....I feel that the future prospects of these two products (Generx & Excellage) are looking very positive," Zhang said.
Now there is a BUY SIGNAL!!
To add icing on the cake:
-With a Low FLOAT of just over 6 million shares TaxuCardium Pharmaceuticals (CRXM) will move on air!!
-From a technical aspect the charts show TaxuCardium Pharmaceuticals (CRXM) getting ready break out and run hard, now is the time to BUY!"
http://www.thelion.com/bin/forum.cgi?sf=CRXM&msg=0&cmd=r&t=
CRXM low float biotech getting ready to breakout
CRXM Low float biotech getting ready to run